Prostate Cancer (PC) is a type of cancer that is often diagnosed at very early stages due to improved detection among man in the Western World. Current imaging techniques are not optimal to determine extent of minimal early stage PC even though this is of great clinical importance. Human PC and high-grade PIN have shown high Gastrin-Releasing Peptide Receptor (GRPR) expression, while normal prostate tissue and BPH revealed to be predominantly GRPR-negative. Radiolabelled GastrinReleasing Peptide (GRP) or bombesin (BN) analogues targeting the GRPR can be used as non-invasive tools to diagnose, monitor and potentially treat PC. These BN analogues have already proven to be able to image PC in both tumour-bearing mice and clinical patients showing no important side effects.
Introduction
The medical specialism of nuclear medicine focuses on the application of radiolabelled tracers for scintigraphic imaging or radionuclide therapy of disease.
Molecular nuclear medicine holds the unique potential of being able to find, diagnose and treat disease as well as to monitor treatment response.
The current evolution of knowledge in molecular biology has resulted in new targets to detect human cancer specifically. New developments in (radio)chemistry have improved molecular delivery of radionuclides to disease-target sites.
Consequently this has resulted in the generation of novel tracers. Technical developments in scintigraphic instruments and reconstruction software have improved imaging modalities allowing small-animal scintigraphic techniques useful for experimental nuclear research of, especially rodent, disease models. See for review (1) .
In oncology radioactive iodine introduced in the early 1950s and the widely This technique is based on targeting specific receptors that are overexpressed in tumor compared to normal tissue with highly selective radiolabelled peptides for specific imaging and monitoring. Linked to appropriate therapeutic radionuclides these peptides can also be used as radiotherapeutics in peptide receptor radionuclide therapy (PRRT).
In order to bring peptide-receptor based modalities into the clinic, radiopharmaceuticals with high affinity and high specificity for preferably cancerspecific receptors are required allowing visualisation and quantification of radioactivity in the tumour in a reproducible and repeatable manner. See for review (2) . Somatostatin is a well-known peptide, of which analogues have been implemented successfully in the clinics to visualise and treat various neuroendocrine tumours (3, 4) .
This review focuses on the use of the Gastrin-Releasing Peptide Receptor (GRPR) as a target for imaging and radionuclide therapy of prostate cancer (PC) using radiolabelled bombesin (BN) analogues. The potential of these peptides for their use in early diagnosis, monitoring and therapy of PC will be discussed.
Prostate cancer
PC is the most frequently diagnosed cancer among men in the Western world and is the third most common cause of death (5) . Specific antigen (PSA) PSA has been increasingly used to detect PC (6), although it has limited diagnostic specificity and prognostic value (7) . PET metabolic radiotracers such as 18 F-FDG, 11 C-choline and 11 C-acetate have been intensively studied for imaging PC. 18 F-FDG was found to have a low accuracy in primary staging of PC mainly due to low metabolic glucose activity and urinary excretion of the metabolic tracer [10] . Choline and acetate PET was reported useful for staging of LN disease [10, 11] .
ProstaScint ( 111 In-capromab pendetide), a monoclonal antibody against prostate-specific membrane antigen (PSMA) as a target, is the only nuclear imaging application for PC-specific imaging. It has been approved by the American Food and Drug Administration and is put to practice for diagnostic imaging and staging of LN metastasis of PC (12) .
An alternative target for PC imaging may be the GRPR using radiolabelled BN analogues.
BN for peptide-targeted imaging of PC
Gastrin-Releasing Peptide (GRP) is a 27-amino acid neuropeptide that is the mammalian homologue of the linear tetradecapeptide BN originally isolated from the skin of the frog; Bombina bombina. GRP binds selectively to the GRPR. It shares homology with BN at the amidated C terminal sequence in the final 7 amino acids ( Figure 1 ).
Using tumour autoradiography it has been reported that in human samples
GRPRs are expressed at high density on the cell membranes of prostatic intraepithelial neoplasias (PIN), primary PC and invasive prostatic carcinomas, whereas normal prostate tissue and, in most cases, benign prostate hyperplasia (BPH)
were predominantly GRPR-negative (13) . The underlying molecular mechanisms of aberrant GRPR expression and/or activation in human PC are unknown at present.
GRP interacts with GRPR inducing cell growth in various tumours including PC (14) .
The relation between GRPR and PC stage is still uncertain. PC in xenografts derived from late stage androgen-independent disease showed lower expression of the GRPR than xenografts established from early androgen-dependent PC (15) . Besides in PC GRPR is also over expressed in several other human tumour types and metastases including breast-, colon-, lung-, ovary-, renal, CNS and head or neck squamous cancer (14, 16) .
Four subtypes of the cell surface BN receptor are known. Among them three are mammalian: the NMB receptor (BB 1 ), Gastrin-Releasing Peptide Receptor (GRPR/BB 2 ) and BN receptor subtype 3 (BRS-3/BB 3 ). A fourth receptor, BB 4, is only found in amphibians (14, 17) . The only well characterised receptor to which GRP and BN bind with high affinity is the GRPR (BB2).
Research on GRPR and BN-analogues
The finding of GRPR overexpression in PC and other cancer types stimulated the search for BN/GRP peptide analogues that could bind with high potency to the GRPR.
GRP-antagonistic analogues have been developed to realise antiproliferative effects and indeed this has led to promising growth-inhibitory effects in human GRPRpositive PC cell lines and human PC3-bearing mice (18) . Besides this approach it was also proposed that GRP analogues could be used as molecular tracers for imaging and treatment of PC tumours, when those analogues would be linked to a radioactive agent (13, 19) . This application has been studied in both preclinical and clinical settings.
Synthetic BN analogues can be categorized into two different types based on their structures. Type A-analogues are truncated with only a portion, usually BN [7] [8] [9] [10] [11] [12] [13] [14] at the C terminus, of the peptide retained. This C terminal sequence is generally thought to be essential for receptor recognition, signal transduction, and biologic function ( Figure 1 ). Type B analogues on the other hand are synthesized in full length.
In these analogues usually one or more amino acid residues are selectively replaced.
A type A-analogue is generally thought to be favourable while it is more stable than the full-length type B tetradecapeptides for in vivo applications and still binds to the GRPR adequately (20, 21) . For radiolabelling of GRP-analogues biomolecules are generally designed in a way to keep the labelling site at distance from the receptor-binding site, but at the same time tag the radiometal into the molecule in an irreversible way leading to stable radiolabelled derivatives.
Preclinical
The development of new analogues is mostly aimed at improving the sensitivity and specificity of GRPR targeting. At the moment a valid comparison of available analogues for PC detection is difficult as standardisation between the preclinical studies performed is lacking.
Therefore we recently performed a standardised preclinical study comparing four DOTA-chelated BN agonists and one N4-chelated BN antagonist (manuscript submitted).
GRPR will internalise into the cell when it is activated by an agonistic ligand binding the receptor. Internalisation of the receptor-radioligand complex has always been thought to be a crucial step for optimal imaging and therapy. It would provide essential accumulation and retention of radioactivity in the cell, thus increasing the radioactive signal at the target site. Interestingly, high-affinity somatostatin receptor antagonists that poorly internalise into tumour cells have recently shown an equal or even higher tumour uptake and a higher retention rate in preclinical studies as opposed to agonists, which do internalise (29) . Cescato et al showed that GRPR antagonists may be superior targeting agents compared to GRPR agonists as well (30) . These data suggest a change of paradigm in which the intensified use of antagonistic in preference to agonistic analogues would be justified. No short-term adverse effects were stated (37) . In a phase I study in hormone refractory PC patients aiming at PC therapy, using the 177 Lu-labelled BN analogue AMBA, SPECT imaging revealed lesions in 5 out of 7 patients with adittional high pancreatic uptake of radioactivity (38) . Only very few PET studies have been reported to date for visualisation and quantification of GRPR expression in PC patients. A clinical study using 68 Ga-DOTABOM has been described by Hofmann et al. (40) .
Future prospectives
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